Rory Budihandojo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rory Budihandojo


Rory Budihandojo
Director, Quality Systems Audit
Boehringer Ingelheim Shanghai Pharmaceuticals

Rory Budihandojo is the director of quality systems audit at Boehringer Ingelheim Shanghai Pharmaceuticals. He has more than 20 years of worldwide pharmaceutical experience (including Pfizer, GSK, Schering Plough) with responsibilities in R&D, manufacturing (API and finished dosage), QA, IT, pharmaceutical technology, and quality audit. He performed method, process, facility, utility, equipment, and computer validation, as well as GMP auditing of contract manufacturers, suppliers, and internal audits. He has validated chromatography, LIMS, PLC, SCADA, DCS, DMS, BAS, ERP, SAP, change-control systems, and more. 

He was a member of PhRMA and PDA CSV Committee, and a founding member of GAMP Americas, and now serves as the vice-chairman and as a global GAMP Council member. He has published several articles in computer validation and was the lead author of PDA Technical Report No. 31. He serves on the editorial board of Pharmaceutical Technology, BioPharm International, Pharma Magazine, Pharm Tech Europe, and Pharmaceutical Engineering. He has a diploma in electronics, and degrees in chemistry and mathematics.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here